Novartis AG ADR (NVS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $303.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novartis AG ADR (NVS) Stock Forecast
Analysts expect Novartis AG ADR (NVS) to earn $9.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $57.76B. Of 11 analysts, 5 rate the stock Buy or Strong Buy, 4 Hold and 2 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $9.93.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.55, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 45% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 27.3% |
| Buy | 2 | 18.2% |
| Hold | 4 | 36.4% |
| Sell | 1 | 9.1% |
| Strong Sell | 1 | 9.1% |
- Consensus
- Hold
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.5% and revenue estimates rise 6.8%.
- Fiscal year ending Dec 31, 2026
- $9.07
- EPS consensus, revenue $57.76B
- Fiscal year ending Dec 31, 2027
- $9.93
- EPS consensus, revenue $61.71B
- Fiscal year ending Dec 31, 2028
- $10.75
- EPS consensus, revenue $64.05B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $9.07 | $8.67 to $9.38 | 8 | $57.76B | $56.47B to $58.86B | 19 |
| Dec 31, 2027 | $9.93 | $9.30 to $10.49 | 9 | $61.71B | $59.72B to $64.71B | 20 |
| Dec 31, 2028 | $10.75 | $10.41 to $11.24 | 7 | $64.05B | $62.50B to $66.29B | 8 |
Quarterly Estimates
The EPS consensus is $2.27 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.27 | $2.05 to $2.43 | 12 | $15.01B | $13.89B to $16.00B | 13 |
| Mar 31, 2027 | $2.27 | $2.21 to $2.33 | 2 | $14.31B | $14.05B to $14.57B | 2 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 5 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.8% from $8.82.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $9.07 | $9.16 | $8.83 | $8.85 | $8.82 | +2.8% |
| Fiscal year ending Dec 31, 2027 | $9.93 | $9.94 | $9.80 | $9.84 | $9.87 | +0.6% |
| Quarter ending Mar 31, 2027 | $2.27 | $2.27 | $2.33 | $2.33 | $2.33 | -2.6% |
Frequently Asked Questions About NVS
What is the NVS stock forecast?
Consensus analyst estimates put Novartis AG ADR's EPS at $9.07 for the fiscal year ending Dec 31, 2026, on revenue of $57.76B. The consensus rating from 11 analysts is Hold.
How do analysts rate NVS stock?
Of 11 analysts covering Novartis AG ADR, 3 rate it Strong Buy, 2 Buy, 4 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from NVS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.07, with estimates from $8.67 to $9.38 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.93, with estimates from $9.30 to $10.49 from 9 analysts.
What revenue do analysts expect from Novartis AG ADR next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $57.76B, with estimates from $56.47B to $58.86B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $61.71B, with estimates from $59.72B to $64.71B.
How many analysts cover NVS?
11 analysts rate Novartis AG ADR stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts